プレジデンシャルシンポジウム2 骨髄増殖性腫瘍の新時代

[PSY2-5] MPN disease burden: lessons learned from MPN patients

Ruben A Mesa (UT Health San Antonio MD Anderson Cancer Center, Hematology, United States of America)

Dr. Ruben Mesa is the director at the Mays Cancer Center, the newly named center at UT Health San Antonio MD Anderson Cancer Center. Dr. Mesa’s has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials. He was a co-leader contributing to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. He is currently leading the investigation of several other drugs for these types of cancers. Dr. Mesa was elected to the Board of Directors of the Leukemia and Lymphoma Society, and sits on the board of the MPN Education Foundation After earning degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign, Dr. Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology.